7 Review of guidance

7.1 New treatments for chronic hepatitis C are awaiting marketing authorisation. According to clinical experts the approach to treating hepatitis C is likely to change rapidly next year because of the new technologies becoming available. The guidance on this technology will be considered for review within 1 year of publication, when other published guidance for hepatitis C is also reviewed. The Guidance Executive will decide whether the technology should be reviewed based on information gathered by NICE, and in consultation with consultees and commentators.

Andrew Dillon
Chief Executive
February 2015